1. Home
  2. SIFY vs CGEM Comparison

SIFY vs CGEM Comparison

Compare SIFY & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sify Technologies Limited

SIFY

Sify Technologies Limited

HOLD

Current Price

$15.67

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$17.61

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIFY
CGEM
Founded
1995
2016
Country
India
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
SIFY
CGEM
Price
$15.67
$17.61
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$30.13
AVG Volume (30 Days)
36.5K
534.9K
Earning Date
04-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$14.34
$5.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.40
$5.68
52 Week High
$17.85
$19.43

Technical Indicators

Market Signals
Indicator
SIFY
CGEM
Relative Strength Index (RSI) 57.42 52.19
Support Level $14.54 $17.19
Resistance Level $15.81 $19.10
Average True Range (ATR) 0.58 0.96
MACD 0.20 -0.12
Stochastic Oscillator 90.05 58.82

Price Performance

Historical Comparison
SIFY
CGEM

About SIFY Sify Technologies Limited

Sify Technologies Ltd is a provider of corporate network services in India. It offers converged Information and Communication Technology (ICT) solutions comprising Network- Connectivity services, Data Center services and Digital Services which include Cloud and Managed services, Applications Integration services and Technology Integration services. The company operates in three segments; Network Connectivity services which consists of domestic data, international data, wholesale voice. Data Center Services which consists of co-location services, cross connects and other allied managed services. Digital Services which consists of Cloud and Managed Services, Network Managed Services, Applications Integration Services, Technology Integration Services. Key revenue is from Network.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: